Join SightNation!

Become a citizen of our interactive community. Collaborate and network with your colleagues and trusted peers. Membership is free!

Connect with Colleagues

Link up with professionals all over the nation. Share your ideas, thoughts and opinions. Collaborate on difficult cases and offer your insights.

Communicate and Educate

Discuss new and important issues with your colleagues. Share your insights to help improve patient counseling. Post questions to your peers.

Learn and Advance

Take CE courses and rate courses for your peers. Find and apply for the newest jobs. Stay up-to-date on the latest eye care industry news.


Engage with SightNation citizens to help create real reform on issues affecting the industry. Start or join groups about the issues most important to you.

Create an account and receive access to the personalized box below.

Apply for Citizenship!
view counter

What’s Going On Across the Nation

New Blog Postings

SightNation News

Featured News

Ranibizumab Restores Diabetic Vision Loss - 04.16.2015

Ranibizumab, commonly used to treat age-related vision loss, also reverses vision loss caused by diabetes among Hispanic and non-Hispanic whites, according to a new study led by investigators from the More »

Featured News

Lifitegrast NDA Gets Priority Review for the Treatment of Dry-Eye Disease - 04.15.2015

Shire plc announced that the FDA has accepted for filing the New Drug Application for lifitegrast, an investigational treatment for dry-eye disease in adults, and gained a Priority Review designation. More »

Featured News

Successful Outcomes Reported for Phase III Study of IBI-10090 to Treat Inflammation Associated With Cataract Surgery - 04.13.2015

Icon Bioscience Inc. reported that Phase III data show significantly positive outcomes for IBI-10090 compared to placebo in treating inflammation associated with cataract surgery. More »

Avalanche Biotechnologies and the University of Washington to Develop Gene Therapy Medicines for Color Blindness - 04.10.2015

Avalanche Biotechnologies has entered into an exclusive license agreement with the University of Washington to develop products based on Avalanche's proprietary Ocular BioFactory Platform for the trea More »

Copyright © 2010 Jobson Medical Information LLC. All Rights Reserved.